The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.

The FDA is adding a new boxed warning to include information that anaphylaxis can occur at any time, from as early as after ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

For more information about injection site reaction and headache, see “Side effect specifics.” Note: After the FDA approves a drug, it tracks and reviews side effects of the medication.

‘Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review’ by Benjamin R. Underwood et al. was published in Alzheimer’s and Dementia: Translational ...

"The almond-containing product was distributed in packaging that did not reveal the presence of almonds," the FDA said.